Alexander Gutfraind1, Lauren Ancel Meyers2. 1. School of Public Health, University of Illinois at Chicago Department of Medicine, Loyola University Medical Center, Maywood, Illinois. 2. Department of Integrative Biology, University of Texas at Austin Santa Fe Institute, New Mexico.
Abstract
BACKGROUND: To combat the 2014-2015 Ebola virus disease (EVD) epidemic in West Africa, the World Health Organization urged the rapid evaluation of convalescent whole blood (CWB) and plasma (CP) transfusion therapy. However, the feasibility and likely impacts of broad implementation of transfusions are yet unknown. METHODS: We extended an Ebola virus transmission model published by the Centers for Disease Control and Prevention to include hospital-based convalescent donations and transfusions. Using recent epidemiological estimates for EVD in Liberia and assuming that convalescent transfusions reduce the case-fatality rate to 12.5% (range, 7.5%-17.5%), we projected the impacts of a countrywide ramp-up of transfusion therapy. RESULTS: Under the 10% case-hospitalization rate estimated for Liberia in September 2014, large-scale CP therapy is expected to save 3586 lives by October 2015 (3.1% mortality reduction; 95% confidence interval [CI], .52%-4.5%). Under a higher 30% hospitalization rate, CP transfusions are expected to save 151 lives (0.9% of the total; 95% CI, .21%-11%). CONCLUSIONS: Transfusion therapy for EVD is a low-cost measure that can potentially save many lives in West Africa but will not measurably influence the prevalence. Under all scenarios considered, CP transfusions are predicted to achieve greater reductions in mortality than CWB.
BACKGROUND: To combat the 2014-2015 Ebola virus disease (EVD) epidemic in West Africa, the World Health Organization urged the rapid evaluation of convalescent whole blood (CWB) and plasma (CP) transfusion therapy. However, the feasibility and likely impacts of broad implementation of transfusions are yet unknown. METHODS: We extended an Ebola virus transmission model published by the Centers for Disease Control and Prevention to include hospital-based convalescent donations and transfusions. Using recent epidemiological estimates for EVD in Liberia and assuming that convalescent transfusions reduce the case-fatality rate to 12.5% (range, 7.5%-17.5%), we projected the impacts of a countrywide ramp-up of transfusion therapy. RESULTS: Under the 10% case-hospitalization rate estimated for Liberia in September 2014, large-scale CP therapy is expected to save 3586 lives by October 2015 (3.1% mortality reduction; 95% confidence interval [CI], .52%-4.5%). Under a higher 30% hospitalization rate, CP transfusions are expected to save 151 lives (0.9% of the total; 95% CI, .21%-11%). CONCLUSIONS: Transfusion therapy for EVD is a low-cost measure that can potentially save many lives in West Africa but will not measurably influence the prevalence. Under all scenarios considered, CP transfusions are predicted to achieve greater reductions in mortality than CWB.
Authors: Martin I Meltzer; Charisma Y Atkins; Scott Santibanez; Barbara Knust; Brett W Petersen; Elizabeth D Ervin; Stuart T Nichol; Inger K Damon; Michael L Washington Journal: MMWR Suppl Date: 2014-09-26
Authors: Gene Garrard Olinger; James Pettitt; Do Kim; Cara Working; Ognian Bohorov; Barry Bratcher; Ernie Hiatt; Steven D Hume; Ashley K Johnson; Josh Morton; Michael Pauly; Kevin J Whaley; Calli M Lear; Julia E Biggins; Corinne Scully; Lisa Hensley; Larry Zeitlin Journal: Proc Natl Acad Sci U S A Date: 2012-10-15 Impact factor: 11.205
Authors: Peter B Jahrling; Joan B Geisbert; James R Swearengen; Thomas Larsen; Thomas W Geisbert Journal: J Infect Dis Date: 2007-11-15 Impact factor: 5.226
Authors: Xiangguo Qiu; Jonathan Audet; Gary Wong; Lisa Fernando; Alexander Bello; Stéphane Pillet; Judie B Alimonti; Gary P Kobinger Journal: Sci Rep Date: 2013-11-28 Impact factor: 4.379
Authors: Xiangguo Qiu; Gary Wong; Jonathan Audet; Alexander Bello; Lisa Fernando; Judie B Alimonti; Hugues Fausther-Bovendo; Haiyan Wei; Jenna Aviles; Ernie Hiatt; Ashley Johnson; Josh Morton; Kelsi Swope; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Michael H Pauly; Jesus Velasco; James Pettitt; Gene G Olinger; Kevin Whaley; Bianli Xu; James E Strong; Larry Zeitlin; Gary P Kobinger Journal: Nature Date: 2014-08-29 Impact factor: 49.962
Authors: Tansy Edwards; Malcolm G Semple; Anja De Weggheleire; Yves Claeys; Maaike De Crop; Joris Menten; Raffaella Ravinetto; Sarah Temmerman; Lutgarde Lynen; Elhadj Ibrahima Bah; Peter G Smith; Johan van Griensven Journal: Clin Trials Date: 2016-01-14 Impact factor: 2.486
Authors: O Garraud; F Heshmati; B Pozzetto; F Lefrere; R Girot; A Saillol; S Laperche Journal: Transfus Clin Biol Date: 2016-01-06 Impact factor: 1.406